Longboard Pharmaceuticals, Inc. (LBPH) NASDAQ
$34.86 0.97 (2.86%)
Market Cap: $1.36B
As of 09/06/24 04:00 PM EDT. Market closed.
Longboard Pharmaceuticals, Inc. (LBPH)
NASDAQ
$34.86
0.97 (2.86%)
Market Cap: $1.36B
As of 09/06/24 04:00 PM EDT. Market closed.
Add to Portfolio
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kevin R. Lind
Full Time Employees
50
CEO Compensation (Base)
$610,000
CEO Compensation (Total)
$2.05M
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kevin R. Lind
Full Time Employees
50
CEO Compensation (Base)
$610,000
CEO Compensation (Total)
$2.05M
Address
4275 Executive Square, CA, La Jolla, 92037.
PRICE CHART FOR LONGBOARD PHARMACEUTICALS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$33.75
Previous Close
$33.89
Days Range
$33.75 - $35.31
52 week range
$3.60 - $40.48
Volume
225,057
Avg. Volume (30 days)
634,966
Market Cap
$1.36B
Dividend Yield
-
P/E
(16.14)
Shares Outstanding
38,899,519
Open
$33.75
Previous Close
$33.89
Days Range
$33.75 - $35.31
52 week range
$3.60 - $40.48
Volume
225,057
Avg. Volume (30 days)
634,966
Market Cap
$1.36B
Dividend Yield
-
P/E
(16.14)
Shares Outstanding
38,899,519
FINANCIAL STATEMENTS FOR LONGBOARD PHARMACEUTICALS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR LONGBOARD PHARMACEUTICALS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Lind Kevin Robert | CEO | Aug 12, 2024 | Option Exercise | $3.15 | 82,482 | 259,995 | 430,932 | Aug 13, 2024, 06:03 PM |
| Kaye Randall | CMO | Aug 12, 2024 | Option Exercise | $4.35 | 16,667 | 72,501 | 34,587 | Aug 13, 2024, 06:01 PM |
| Kaye Randall | CMO | Jan 23, 2024 | Buy | $24.82 | 100 | 2,482 | 100 | Aug 13, 2024, 06:01 PM |
| Kaye Randall | CMO | Aug 12, 2024 | Sale | $34.73 | 16,667 | 578,804 | 24,111 | Aug 13, 2024, 06:01 PM |
| Kaye Randall | CMO | Jun 25, 2024 | Sale | $20.87 | 100 | 2,087 | 0 | Aug 13, 2024, 06:01 PM |
| ARENA PHARMACEUTICALS INC | Former 10% Owner | Jan 25, 2024 | Sale | $24.25 | 3,978,540 | 96,479,595 | 0 | Jan 29, 2024, 04:37 PM |
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Lind Kevin Robert | CEO | 08/12/2024 | 259,995 |
| Kaye Randall | CMO | 08/12/2024 | 72,501 |
| Kaye Randall | CMO | 01/23/2024 | 2,482 |
| Kaye Randall | CMO | 08/12/2024 | 578,804 |
| Kaye Randall | CMO | 06/25/2024 | 2,087 |
| ARENA PHARMACEUTICALS INC | Former 10% Owner | 01/25/2024 | 96,479,595 |
FUNDS WITH A POSITION IN LONGBOARD PHARMACEUTICALS, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 3,289,119 | 1.18% | No change | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 2,940,500 | 0.38% | No change | Event Driven, Value |
| BLACKROCK INC. | 2,368,451 | 0.00145% | 26.91% | Other |
| VIKING GLOBAL INVESTORS LP | 1,752,656 | 0.21% | 5.65% | Growth At A Reasonable Price |
| GEODE CAPITAL MANAGEMENT, LLC | 682,391 | 0.00162% | 22.71% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 488,793 | 0.13% | 25.82% | Growth |
| CANDRIAM S.C.A. | 225,917 | 0.04% | New | Other |
| PLATINUM INVESTMENT MANAGEMENT LTD | 114,047 | 0.12% | -10.23% | Growth At A Reasonable Price, Value |
| RENAISSANCE TECHNOLOGIES LLC | 71,400 | 0.00242% | Exited | Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 51,596 | 0.09% | -4.55% | Value |
| ALPS ADVISORS INC | 26,239 | 0.00487% | New | Other |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 9,624 | 0.00362% | Exited | Other |
BUYBACK ANNOUNCEMENT(S) FOR LONGBOARD PHARMACEUTICALS, INC.
LOADING...